|Articles|July 28, 2022
Boehringer Ingelheim to Use Seqster Platform
Patients in all studies can consent to longitudinal data use to accelerate RWE
Advertisement
Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.
Read more about the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Breaking Out of AI Pilot Mode in Clinical Development
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
5